StockData
AVITA Medical, Inc. logo

AVITA Medical, Inc. (RCEL) stock

RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$15.63−0.57 (-3.52%)

Close on Nov 13, 2026Market cap $483.39MP/E –Yield –

Earnings

AVITA Medical's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 11, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$26.10M
+52.6% on a year earlier
EPS, Q3 FY2026
-$0.20
-$0.46 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of AVITA Medical's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 5, 2026after the close$26.10M+52.6%-$0.20Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026during market hours$21.70M+17.9%-$0.25Release
Q1 FY2026ended Mar 31, 2026May 14, 2026during market hours$19.30M+4.3%-$0.35Release
Q4 FY2025ended Dec 31, 2025Feb 12, 2026during market hours$17.60M-4.3%-$0.38Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025during market hours$17.10M-12.3%-$0.46Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours$18.40M+21.1%-$0.38Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$18.50M+66.7%-$0.53Release
Q4 FY2024ended Dec 31, 2024Feb 13, 2025during market hours$18.40M+29.6%-$0.44Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024during market hours$19.50M+43.4%-$0.62Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024during market hours$15.20M+28.8%-$0.60Release
Q1 FY2024ended Mar 31, 2024May 13, 2024during market hours$11.10M+4.7%-$0.73Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

AVITA Medical's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
revenueQ4 FY2026$24.90M – $26.90M–NewNov 5, 2026
full-year 2026 revenue guidanceFY2026$92.00M – $94.00M$80.00M – $85.00MRaisedNov 5, 2026
revenueFY2026$86.00M – $89.00M$80.00M – $85.00MRaisedAug 6, 2026
year-over-year growthFY2026+20% – +24%+12% – +19%RaisedAug 6, 2026

Guidance vs results

The last range AVITA Medical gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$70.00M – $74.00M$71.60MΣ4QWithin range
Q4 FY2024Revenue$22.30M – $24.30M$18.40MBelow range
Q4 FY2024Revenue growth+58% – +72%+29.58%Below range
Q3 FY2024Revenue$19.00M – $20.00M$19.50MWithin range
Q2 FY2024Revenue$14.30M – $15.30M$15.20MWithin range
Q1 FY2024Revenue$14.80M – $15.60M$11.10MBelow range
Q4 FY2023Revenue$15.30M – $16.30M$14.20MBelow range
Q3 FY2023Revenue$13.00M – $14.00M$13.60MWithin range
Q2 FY2023Revenue$10.70M – $11.70M$11.80MAbove range

Guidance history

Every forecast AVITA Medical put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Gross margin for RECELL products onlyover the coming quarters86% – 90%–
Nov 5, 2026revenueQ4 FY2026$24.90M – $26.90MNew
Nov 5, 2026full-year 2026 revenue guidanceFY2026$92.00M – $94.00MRaised
Aug 6, 2026year-over-year growthFY2026+20% – +24%Raised
Aug 6, 2026revenueFY2026$86.00M – $89.00MRaised
May 14, 2026revenueFY2026$80.00M – $85.00MReaffirmed
Feb 12, 2026revenueFY2026$80.00M – $85.00MNew
Jan 13, 2026growthFY2026+12% – +19%New
Jan 13, 2026Full year 2026 revenueFY2026$80.00M – $85.00MNew
Nov 6, 2025revenueFY2025$70.00M – $74.00MNew
Aug 7, 2025revenueFY2025+19% – +27%Lowered
Aug 7, 2025revenue guidanceFY2025$76.00M – $81.00MLowered
May 8, 2025Commercial revenue growthFY2025+55% – +65%New
May 8, 2025Commercial revenueFY2025$100.00M – $106.00MReaffirmed
Feb 13, 2025Commercial revenueFY2025$100.00M – $106.00MReaffirmed
Jan 7, 2025Commercial revenueFY2025$100.00M – $106.00MNew
Nov 7, 2024Commercial revenue growthQ4 FY2024+58% – +72%New
Nov 7, 2024Commercial revenueQ4 FY2024$22.30M – $24.30MNew
Nov 7, 2024Commercial revenue growthFY2024+37% – +41%New
Nov 7, 2024Commercial revenueFY2024$68.00M – $70.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases AVITA Medical filed with the SEC as exhibits to Form 8-K or 6-K

  1. AVITA Medical Reports Third Quarter Results
    Results
  2. AVITA Medical Reports Second Quarter Results,
    Results
  3. AVITA Medical Reports First Quarter 2026 Financial Results
    Results
  4. AVITA Medical Names Cary Vance as Chief Executive Officer
    Update
  5. AVITA Medical Reports Fourth Quarter and Full Year 2025 Financial Results
    Results
  6. AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook
    Results
  7. AVITA® Medical Reports Third Quarter 2025 Financial Results
    Results
  8. AVITA Medical Announces CEO Transition
    Update
  9. AVITA Medical Successfully Completes Australian Equity Raise
    News
  10. AVITA Medical Reports Second Quarter 2025 Financial Results, Updates Full-Year Guidance, and Highlights Continued Clinical Innovation
    Results
  11. AVITA Medical Reports First Quarter 2025 Financial Results
    Results
  12. AVITA Medical Announces Exclusive Manufacturing and Distribution Agreements with Stedical Scientific
    Update
  13. AVITA Medical Reports Fourth Quarter and Full Year 2024 Financial Results
    Results
  14. AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance
    Results
  15. AVITA Medical Reports Third Quarter Financial Results
    Results

See a number that looks wrong?